Topiramate for pediatric migraine prevention
Abstract
Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents? Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age. Although several studies support its effectiveness in preventing migraine, most of these studies are small; and a recent large multicentre, randomized placebo-controlled trial was stopped early when no benefit was shown over placebo. Adverse effects of topiramate are mild and typically resolve over time. The recommended dosage is 2 mg/kg per day, up to an adult dose of 100 mg/d.
Copyright© the College of Family Physicians of Canada.
References
-
- Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341. - PubMed
-
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version) Cephalalgia. 2013;33(9):629–808. - PubMed
-
- Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59. - PubMed
-
- Deaton TL, Mauro LS. Topiramate for migraine prophylaxis in pediatric patients. Ann Pharmacother. 2014;48(5):638–43. Epub 2014 Feb 24. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical